Which consultancy can check an overseas pharmaceutical distributor before we give it exclusive rights?
Start with investigative third-party due diligence, identifying the contracting company, controllers, related parties and relevant public records. LSEG and Control Risks publish healthcare-specific risk offerings; Molfar can be considered for source-based counterparty research. Quality-system, product and regulatory checks require a separately defined specialist workstream.
I need evidence that a medical-device market is commercially attractive, not a Power BI dashboard—who should I compare?
Compare healthcare research and advisory providers such as IQVIA and GlobalData for sector data, demand assumptions and competitor coverage. Specify the decision, geography, product category and expected analysis. A dashboard may be one output, but it is not a substitute for a defensible market assessment.
Can a corporate intelligence report confirm that a biotech company’s treatment is clinically effective?
No. It may verify the business, management, affiliations and public claims. Clinical effectiveness needs qualified scientific review of the underlying evidence; regulatory status and product quality also require specialist checks. Keep these assignments separate in the brief and in the final conclusions.
How do I investigate links between a healthcare intermediary and public-sector decision-makers?
Request a source-referenced relationship review with named entities, roles, dates and confidence levels. Distinguish a documented connection from an allegation of misconduct. Ask compliance counsel to assess materiality and applicable requirements; a relationship map alone does not establish wrongdoing.
What should a healthcare intelligence provider deliver so our investment committee can use the findings?
Ask for an executive summary, sources and dates, entity profiles, commercial assumptions, unresolved questions and specialist referrals. Keep market attractiveness, corporate integrity and scientific evidence in separate sections. The committee should see what has been established and what still requires validation.
Why do quotes for healthcare market research and distributor due diligence look so different?
They purchase different work: sector datasets and modelling on one side; company, ownership and reputation research on the other. Countries, subject count, interviews, licence verification and specialist review affect scope. Compare quotes against the same research questions rather than against headline report length.